Mesoblast (MESO) EBITDA (2015 - 2023)

Mesoblast has disclosed EBITDA across 9 years of filings, most recently posting $3.0 billion for Q2 2023.

• EBITDA for Q2 2023 came in at $3.0 billion, changed 0.07% year-over-year; the trailing twelve-month figure through Jun 2023 was $680.0 million (up 5368.24% YoY), and the FY2025 annual result was -$62.0 million, up 4.09% from the prior year.
• EBITDA came in at $3.0 billion for Q2 2023 at Mesoblast, up from -$1.2 billion in the prior quarter.
• In the past five years, EBITDA ranged from a high of $7.0 billion in Q2 2021 to a low of -$1.6 billion in Q1 2021.
• The 5-year median for EBITDA is -$549.5 million (2019), against an average of $297.9 million.
• Across the five-year window, EBITDA surged 19799.2% in 2020 and plunged 11886.21% in 2021, its largest moves.
• Mesoblast's EBITDA stood at -$734.9 million in 2019, then jumped by 101.36% to $10.0 million in 2020, then slumped by 9855.67% to -$978.4 million in 2021, then advanced by 15.17% to -$830.0 million in 2022, then surged by 457.54% to $3.0 billion in 2023.
• The last three EBITDA figures came in at $3.0 billion (Q2 2023), -$1.2 billion (Q1 2023), and -$830.0 million (Q4 2022), per Business Quant data.